Evidence map›Paper›PMID 41346619›Full record

ArticleFrontiers in immunology2025

Prognostic differential subpopulation classification and immunotherapy response prediction in pancreatic cancer patients based on the gene features of necrotizing apoptosis.

Kaili Liao, Zheng Fu, Xinrui Liu, Xiajing Yu, Linfeng Jin, Jinting Cheng, Dongyu Yang, Kun Ai, Ziqian Liu, Daixin Guo and 13 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Kaili Liao *Jiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Zheng Fu *The First Clinical Medical College, Nanchang University, Jiangxi, Nanchang, China.
Xinrui Liu *Queen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Xiajing Yu *Jiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Linfeng JinJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Jinting ChengSchool of Public Health, Nanchang University, Nanchang, Jiangxi, China.
Dongyu YangQueen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Kun AiQueen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Ziqian LiuQueen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Daixin GuoSchool of Public Health, Nanchang University, Nanchang, Jiangxi, China.
Shuai LiuThe Second Clinical Medical College, Nanchang University, Nanchang, Jiangxi, China.
Xiwen YanQueen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Zijia LiQueen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Mingchen XuQueen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Xiya YanQueen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Jingyi GanThe Forth Clinical Medical college, Nanchang University, Nanchang, Jiangxi, China.
Zhiwen ChengDepartment of Colorectal Surgery, The Second Hospital of Zhejiang University School of Medicine, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Hangzhou, Zhejiang, China.
Wenqing ZhuThe First Clinical Medical College, Nanchang University, Jiangxi, Nanchang, China.
Mingxiu CaiQueen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Wanqian XuQueen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Ziying LiQueen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Jiasheng XuDepartment of Colorectal Surgery, The Second Hospital of Zhejiang University School of Medicine, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Hangzhou, Zhejiang, China.
Xiaozhong WangJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study aims to explore the prognostic significance of necroptosis-related genes in pancreatic cancer. Methods: First, clustering analysis was performed on 15 necroptosis-related genes, which led to the identification of two distinct NRG subtypes. Differential expression analysis revealed 495 genes associated with prognosis, which were subsequently used for a second round of clustering. Next, a prognostic model was constructed using seven key genes, and patients were classified into high-risk and low-risk groups. External cohort data were used to validate the prognostic model. Spearman correlation analysis was conducted to examine the relationship between the most important biomarker, CHST11, and the 15 NRG genes. Additionally, three single-cell datasets, along with Mendelian randomization and spatial transcriptomics analyses, were utilized to further investigate the associations between CHST11, immune therapy, immune cells, and malignant epithelial cells. Results: NRGcluster A and geneCluster B largely overlapped, with most patients classified into the low-risk group. Among the 15 NRG genes, 11 exhibited significant expression differences between the high-risk and low-risk groups. CHST11 was identified as the most important prognostic biomarker and showed significant correlations with 13 NRG genes. Further analysis revealed potential mechanisms of action for CHST11. Discussion: This study, through multi-omics data, reveals that CHST11 may be associated with necroptosis and is closely related to the malignant prognosis of pancreatic cancer.

Indexed as

ApoptosisBiomarkers, TumorImmunotherapyNecroptosisPancreatic NeoplasmsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisTranscriptomeBiomarkers, Tumorcarbohydrate sulfotransferase 11multi-omicsnecrotizing apoptosispancreatic cancerspatial transcriptomics

Identifiers

PMID41346619
PMCPMC12672444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.